Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of VSA003 in Chinese Adult Healthy Volunteers

NCT05851066 is registered in ClinicalTrials.gov with Visirna Therapeutics HK Limited as lead sponsor.

NCT NCT05851066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05851066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of VSA003 in Chinese Adult Healthy Volunteers
Lead sponsor
Visirna Therapeutics HK Limited
Phase
Phase 1
Overall status
Completed
Start date
June 1, 2023
Completion date
May 7, 2024
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dyslipidemias, familial hypercholesterolemia, hypertriglyceridemia